 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || AM003 / Aummune
Trial completion, Trial completion date: AM003-FIH-001: Study of AM003 in Patients With Locally Advanced and Metastatic Solid Tumors (clinicaltrials.gov) - Jan 28, 2025
P1, N=12, Completed, Sponsor: Aummune Ltd.
Active, not recruiting --> Completed | Trial completion date: Jan 2025 --> Oct 2024
- AM003 / Aummune
Safety and efficacy of AM003, a first-in-class individualized immunotherapy, in a basket of advanced solid tumors: results from a phase1 study (Exhibit Halls AB - George R. Brown Convention Center) - Oct 4, 2024 - Abstract #SITC2024SITC_789;
P1
Ethics Approval The study was approved by all relevant LECs and regulatory authorities. All study participants gave informed consent prior to enrollment.
- || AM003 / Aummune
Enrollment closed, Trial completion date: AM003-FIH-001: Study of AM003 in Patients With Locally Advanced and Metastatic Solid Tumors (clinicaltrials.gov) - Aug 1, 2024
P1, N=12, Active, not recruiting, Sponsor: Aummune Ltd.
All study participants gave informed consent prior to enrollment. Recruiting --> Active, not recruiting | Trial completion date: Jun 2024 --> Jan 2025
- AM003 / Aummune
Phase 1 study of AM003, a novel individualized immunotherapy, in a basket of advanced solid tumors. (Hall A; Poster Bd #: 159b) - Apr 24, 2024 - Abstract #ASCO2024ASCO_3091;
The DSMB last reviewed the escalation data in January 2024 and concluded that the trial can continue as planned. Enrollment of 136mg dose expansion is ongoing and completion of the trial will be mid 2024.
- AM003 / Aummune
A Novel CpG motif Introduced into a Bispecifc AM003 Compound for the Treatment of Solid Tumors (Hall C) - Oct 6, 2022 - Abstract #SITC2022SITC_1437;
Aummune has initiated a first-in-human clinical study of AM003 in subjects with solid tumors. TLV medical center ethics committee TLVMC – IL – 2205 – 113 – 5 (Animals study) Helsinki approval number 0297-15-TLV (Buffy coat)